Senti Biosciences (Dynamics Special Purpose Corp.) ^{Priced, Nasdaq: SNTI}

We are a newly organized blank check company. While we may pursue an acquisition opportunity in any business, industry, sector, we intend to focus on healthcare-related industries We will pursue investments primarily based in North America. In particular, we intend to focus on companies across the emerging healthcare value chain, life sciences tools, enabling-software, synthetic biology and novel drug discovery and development platforms that enable applications in prevention, diagnosis, treatment and advanced bio-materials. Our management team and Board of Directors consist of our Executive Chair Omid Farokhzad, MD, who is currently Founder, CEO, and Chair of Seer, Inc. (Nasdaq: SEER); our CEO Mostafa Ronaghi, PhD, who was most recently CTO of Illumina (Nasdaq: ILMN); our CFO Mark Afrasiabi, CFA, most recently Senior Partner at Silver Rock Financial; our CBO Rowan Chapman, PhD, a seasoned venture capital investor across the life sciences subsector; independent director Jay Flatley, who served as CEO of Illumina from June 1999 to March 2016 and Chairman until March 2021; independent director David Epstein, formerly CEO of Novartis Pharmaceuticals; and independent director Deep Nishar, Senior Managing Partner of the Softbank Vision Fund. We also have a Chief Scientific Advisor, Professor Robert Langer, who is currently one of twelve Institute Professors at MIT.